As reported by the Institute last month we have received 8 (eight) appeals against the draft guidance on the use of interferon beta in MS. The appeal is an integral part of the Institute's process for developing its guidance for the NHS. All the nationally based organisations involved in the process are provided with the opportunity to make an appeal.
An independent appeal panel will consider these appeals today, the 22nd September 2000, and in line with the Institute's published policies we will inform appellants and stakeholders of the outcome of the appeal as soon as practicably possible. Appeals can either be upheld or rejected.
Communications Director, NICE